Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05724966 | Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma | completed | — | 33 | Thomas LundOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02286830 |
| Prolonged Protection From Bone Disease in Multiple Myeloma(Magnolia) |
| completed |
| Phase 4 |
| 158 |
| Thomas LundOTHER |
| 1 |
| Feb 17, 2023 |
| clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03019640 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03305445 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | completed | Phase 1 | 6 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03836768 | BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | completed | Phase 1 | 20 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04626843 | Intermittent Fasting and CLL/SLL | completed | Phase 1 | 15 | Eleah StringerOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT02257242 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma(BRiM) | completed | Phase 1 | 11 | Brown UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03316209 | Identification of Occupational Exposures in Acute Hematologic Malignancy(RHELYPRO) | completed | — | 205 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03357627 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT00806065 | Study of ENMD-2076 in Patients With Multiple Myeloma | completed | Phase 1 | 13 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04872023 | Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression(IMMUNO-MYELO) | completed | N/A | 5 | Rennes University HospitalOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT02853370 | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma | completed | Phase 2 | 78 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 2 | Feb 1, 2023 | clinicaltrials |
| NCT04859920 | Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region(LymphoVi) | completed | — | 157 | Centre Hospitalier Universitaire DijonOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT00005780 | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma(STORM) | completed | Phase 2 | 202 | Karyopharm Therapeutics IncINDUSTRY | 6 | Jan 26, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02658929 | Study of bb2121 in Multiple Myeloma | completed | Phase 1 | 67 | CelgeneINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03374137 | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia | completed | — | 55 | Hoffmann-La RocheINDUSTRY | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02303119 | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)(FLIRT) | completed | Phase 3 | 221 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | completed | Phase 2 | 136 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | completed | Phase 2 | 55 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02440464 | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | completed | Phase 2 | 57 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT04629430 | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT(HCTDiet) | completed | N/A | 40 | University of VirginiaOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT04918940 | Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma(VAXIMAB) | completed | N/A | 20 | Centre Henri BecquerelOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT00864227 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | completed | Phase 2 | 54 | Medical College of WisconsinOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT02403102 | Imageguided Theranostics in Multiple Myeloma(iTIMM) | completed | — | 61 | Institute of Cancer Research, United KingdomOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT03877055 | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT02158052 | Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease | completed | N/A | 2 | Massachusetts General HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT00664898 | A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT03091127 | Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | completed | — | 705 | AmgenINDUSTRY | 11 | Dec 12, 2022 | clinicaltrials |
| NCT02604511 | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT01364363 | Unrelated Donor Stem Cell Transplantation | completed | N/A | 64 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT03187262 | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 2 | 17 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT02963493 | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(HORIZON) | completed | Phase 2 | 157 | Oncopeptides ABINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT00115700 | Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma | completed | Phase 3 | 150 | Trans Tasman Radiation Oncology GroupOTHER | 3 | Nov 18, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT03200015 | Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT01575925 | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)(POM Renal) | completed | Phase 1 | 25 | CelgeneINDUSTRY | 2 | Nov 4, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Feb 21, 2023source: clinicaltrials